Tenet Healthcare Lifted to $295 as BofA Holds Analyst Conviction

NEW YORK, August 10 —

Tenet Healthcare Corporation (THC) received a $5 BofA price target lift to $295, a rounding-error raise for a company generating $2.2bn in free cash flow.

What Actually Happened

BofA Securities adjusted its Tenet Healthcare price target from $290 to $295, keeping its existing rating intact. The $5 move is a 1.7% increase in the target. At $260.44 per share, the new target implies 13% upside, marginally more than the prior target's 11%.

What this signals is continued conviction, not escalating conviction. BofA's stance was already constructive; this is a model refresh, not a thesis change. When the price target increment is smaller than 2% of the stock price, read it as confirmation, not catalyst.

The more interesting number is buried in the fundamentals. Tenet printed $2.2bn in free cash flow on $21.8bn in TTM revenue, roughly 10% FCF margin for a hospital operator. Hospital businesses are capital-hungry: facilities, equipment, staffing, and malpractice reserves eat cash every quarter. Generating 10% FCF margin in that environment is what keeps a major sell-side desk constructive even when the increment is small.

The Catch

The valuation setup has a detail most coverage will skip. Trailing EPS stands at $25.87, and at $260.44 the stock trades at roughly 10x trailing earnings. But forward P/E is 12.5x. That gap implies consensus is modeling an earnings decline from the trailing figure, whether from one-time items cycling out or from margin pressure ahead.

Revenue grew 6.8% YoY to $21.8bn, which argues against a structural top-line problem. But if the earnings compression is operational rather than accounting, BofA's $295 target rests on a floor that may not be as solid as the price target bump suggests. That question is worth answering before the next report lands.

Bottom Line

THC at $260 is a more compelling setup than a $5 price target adjustment implies. The FCF story is real, the revenue growth is real, and BofA's constructive bias is publicly documented. For value-oriented investors, roughly 10x trailing earnings plus $2.2bn in annual cash generation is a combination worth examining closely.

The specific number to watch next quarter: whether forward EPS estimates revise up or down after the report. If they revise up, the forward multiple tightens and $295 looks conservative. If they revise down, the apparent cheapness on trailing earnings was a mirage. Run the assumptions through the DCF calculator to test where the thesis breaks.

For a full fundamental breakdown on Tenet Healthcare, generate a Basis Report at /stock/thc.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.